A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity.
about
Vaccination against GIP for the treatment of obesityVersatile virus-like particle carrier for epitope based vaccinesA Modular Vaccine Development Platform Based on Sortase-Mediated Site-Specific Tagging of Antigens onto Virus-Like ParticlesEnhanced neutralizing antibody titers and Th1 polarization from a novel Escherichia coli derived pandemic influenza vaccine.Negatively Charged Carbon Nanohorn Supported Cationic Liposome Nanoparticles: A Novel Delivery Vehicle for Anti-Nicotine Vaccine.A vaccine against nicotine for smoking cessation: a randomized controlled trialImmunogenic display of diverse peptides, including a broadly cross-type neutralizing human papillomavirus L2 epitope, on virus-like particles of the RNA bacteriophage PP7Subviral particle as vaccine and vaccine platform.Hypertension Vaccine may be a boon to millions in developing world.Vaccines in the management of hypertension.Resistant hypertension workup and approach to treatmentA cholesterol-lowering VLP vaccine that targets PCSK9Bacterial superglue enables easy development of efficient virus-like particle based vaccines.Modern Medicine: Towards Prevention, Cure, Well-being and Longevity.Construction, expression and immunogenicity of a novel anti-hypertension angiotensin II vaccine based on hepatitis A virus-like particle.Exploiting viral properties for the rational design of modern vaccines.Bacterially produced recombinant influenza vaccines based on virus-like particles.Head-to-Head Comparison of Soluble vs. Qβ VLP Circumsporozoite Protein Vaccines Reveals Selective Enhancement of NANP Repeat Responses.Virus-like display of a neo-self antigen reverses B cell anergy in a B cell receptor transgenic mouse model.Vaccination against type 1 angiotensin receptor prevents streptozotocin-induced diabetic nephropathyInhibition of neointima formation through DNA vaccination for apolipoprotein(a): a new therapeutic strategy for lipoprotein(a)Virus-like particles: flexible platforms for vaccine development.Vaccination, immune and gene therapy based on virus-like particles against viral infections and cancer.Vaccination against nicotine: an emerging therapy for tobacco dependence.Engineering virus-like particles as vaccine platformsThe coming of age of virus-like particle vaccines.Targeted vaccination against the bevacizumab binding site on VEGF using 3D-structured peptides elicits efficient antitumor activity.Induction of mucosal and systemic antibody responses against the HIV coreceptor CCR5 upon intramuscular immunization and aerosol delivery of a virus-like particle based vaccine.Therapeutic vaccine against DPP4 improves glucose metabolism in miceRhesus macaque and mouse models for down-selecting circumsporozoite protein based malaria vaccines differ significantly in immunogenicity and functional outcomesHarnessing Nanoparticles for Immunomodulation and VaccinesUpdate on newer antihypertensive medicines and interventions.Immunodrugs: breaking B- but not T-cell tolerance with therapeutic anticytokine vaccines.Virus-like particles in vaccine development.Therapeutic vaccines for chronic diseases: successes and technical challenges.Therapeutic perspectives in hypertension: novel means for renin-angiotensin-aldosterone system modulation and emerging device-based approaches.Developments in virus-like particle-based vaccines for infectious diseases and cancer.Nanoscale assemblies and their biomedical applications.Are there any new pharmacologic therapies on the horizon to better treat hypertension? A state-of-the-art paper.Development of DNA vaccines as an anti-hypertensive therapy or for anti-angiogenesis.
P2860
Q27300376-8A6289CA-402B-4041-A568-C754F630AF6BQ28748358-475A3CFF-FAFC-4F94-A735-1E14248C3A86Q28834387-163EDE9E-07DF-4545-91D1-A6CF37CCA71FQ30355360-6A033CB5-DA8E-432E-BD4C-04981313B189Q30361416-79CEB75E-D83F-4DDE-B483-D76976F96AEBQ33346321-FBC50C50-0745-4798-BE7A-CC637145A0A7Q33569555-58B739A8-BDE9-45A0-98FE-A9B239A3F1E5Q33812653-8233A619-1002-4DC2-956C-E2D5410CE921Q34033817-C6BAB9A6-D24E-405E-907E-EACCF0B96D69Q34114402-F06202D2-1FAF-4873-8A7C-22CF8AFBC57DQ34460704-725DE929-94B5-4F08-AEC5-675BDE3C9E81Q34496015-AC8AF8F1-E250-427C-9784-1A480117A11CQ34523734-8912219D-D61E-45D2-AA0B-13C77E37F9E3Q34543958-BE7D2C19-312C-4F07-ACB0-51BD35F04B76Q34587965-1F3C9675-FE7E-4078-B6E7-D1F5F1ECF767Q34746490-15E25757-C9F2-420D-B681-B3B053A065DCQ35048127-27843538-FE8D-4E4C-BC89-A77118DB6976Q35841913-4E735AAF-1C7B-4755-BDCD-D5D4476C3AEDQ36383391-DFF76E11-6882-4089-8005-1DC72BCC18C9Q36605186-4BB508CE-7446-440B-98CF-7A07E36FB113Q36736883-52E892E2-4A59-44CD-BDC0-43AB9B8FBB51Q36837144-669286D3-580F-4934-8354-CDA1724A4792Q36897382-66098AFF-74FD-48AA-B61B-6C81D9F37E1FQ36985864-65013818-F7A3-40CA-954E-FAFD4B30D616Q37172342-F5AB1076-B5FA-4B3D-8463-09D9D888A622Q37309265-037A3B74-4DCA-465E-8ADD-82EAE324FD74Q37398065-93A84C84-5467-4310-930D-688EEBB66856Q37461092-D93DACFC-DA5C-44F6-A92A-8DFE10ED04F3Q37687552-3B3DB219-783A-46B0-97E7-8F23F2FAF404Q37696415-097BC701-F6D0-4A45-9CCA-55C1AE8B5EF1Q37727724-993B606D-6675-4E34-B22C-92BC314642E6Q37753547-4030296A-F4E3-4E2A-AEC7-B85426194B00Q37773295-D1C26BB8-68A6-4AED-B07B-68BC55FF2B4AQ37798008-C05402EA-B66B-4C53-8618-8BB279A880C8Q37926764-1E0FCEFC-D268-4562-86DA-A448D04341F2Q37939427-9DD83343-D17C-42CD-BCEC-576D705A337DQ37951525-0CC9BAFD-AB5F-4EA8-A475-904B8928B4E4Q38072847-DA45AE35-EAAE-4661-A636-964AF51F5149Q38208808-7AEEC914-5879-4057-873A-B0A2D0BFC85EQ38352286-E55A3C5C-AC12-47C5-81D2-B9DE8879BAD2
P2860
A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
A vaccine for hypertension bas ...... e I safety and immunogenicity.
@en
A vaccine for hypertension bas ...... e I safety and immunogenicity.
@nl
type
label
A vaccine for hypertension bas ...... e I safety and immunogenicity.
@en
A vaccine for hypertension bas ...... e I safety and immunogenicity.
@nl
prefLabel
A vaccine for hypertension bas ...... e I safety and immunogenicity.
@en
A vaccine for hypertension bas ...... e I safety and immunogenicity.
@nl
P2093
P1476
A vaccine for hypertension bas ...... e I safety and immunogenicity.
@en
P2093
Alain C Tissot
Alma Fulurija
Charlotte Schellekens
Frank Wagner
Gary T Jennings
Hans-Dieter Volk
Juerg Nussberger
Katja Sladko
Kirsten Roubicek
Manfred Rettenbacher
P356
10.1097/HJH.0B013E32800FF5D6
P577
2007-01-01T00:00:00Z